1. Home
  2. Browse Decisions
  3. F.Supp.2d
  4. 858 F.Supp.2d
  5. 858 F.Supp.2d 341 (2012)
 

OSI PHARMACEUTICALS v. MYLAN PHARMACEUTICALS INC.

Civil No. 09-185-SLR.

858 F.Supp.2d 341 (2012)

OSI PHARMACEUTICALS, INC., Pfizer, Inc., and Genentech Inc., Plaintiffs, v. MYLAN PHARMACEUTICALS INC., Defendant.

United States District Court, D. Delaware.

May 1, 2012.

Attorney(s) appearing for the Case

Jack B. Blumenfeld, Esquire and Maryellen Noreika, Esquire of Morris, Nichols, Arsht & Tunnell LLP. Counsel for Plaintiffs. Of Counsel: Leora Ben-Ami, Esquire, Benjamin Hsing, Esquire, Daniel Bogliogi, Esquire and Sapna W. Palla, Esquire of Kaye Scholer LLP.

John C. Phillips, Jr., Esquire and Megan Haney, Esquire of Phillips, Goldman & Spence, P.A. Counsel for Defendant. Of Counsel: James H. Wallace, Jr., Esquire, Mark A. Pacella, Esquire, Matthew J. Dowd, Esquire and Adrienne Johnson, Esquire of Wiley Rein LLP.

OPINION

SUE L. ROBINSON, District Judge.

I. INTRODUCTION

This action arises out of the filing of Abbreviated New Drug Applications ("ANDAs") by Mylan Pharmaceuticals Inc. ("Mylan") and Teva Pharmaceuticals USA, Inc. ("Teva") seeking to market generic versions of Tarceva® (eriotinib tablets), used to treat certain indications of non-small cell lung cancer and pancreatic cancer. Plaintiff OSI Pharmaceuticals, Inc. ("OSI") is the holder of approved...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases